BIG NEWS for skin cancer patients!

Libtayo (cemiplimab), for adults with metastatic or locally advanced cutaneous squamous cell carcinoma (advanced cSCC) when curative surgery and curative radiation is not suitable, is listed on the PBS.

This is an incredible milestone. There has been a high unmet need for treatment options for patients with advanced cSCC. Listing Libtayo on the PBS helps meet this need. Libtayo is the first reimbursed treatment option available specifically for patients for whom curative surgery and radiation is not an option or not suitable.

Skin cancer is Australia's national cancer, and this important PBS listing will help to reduce the burden of the disease.

More here;

https://www.miragenews.com/first-immunotherapy-for-advanced-cutaneous-885819/

Cathy Ellis8 November 2022